Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Oct 23:100886.
doi: 10.1016/j.medj.2025.100886. Online ahead of print.

International expert consensus on gene therapy for hereditary hearing loss: Based on clinical trials

Affiliations
Free article

International expert consensus on gene therapy for hereditary hearing loss: Based on clinical trials

Xintai Fan et al. Med. .
Free article

Abstract

Background: Hereditary hearing loss is one of the most common disabling disorders in children and lacks effective pharmacological treatments. Recent breakthroughs in OTOF gene therapy clinical trials necessitate standardized frameworks to guide emerging therapies. This study aims to establish the first international consensus on the clinical application of gene therapy for hereditary hearing loss.

Methods: A modified Delphi process was conducted from March 2024 to March 2025, involving 46 multidisciplinary experts from several countries across otology, genetics, audiology, gene therapy, and hearing rehabilitation. After a systematic literature review, as well as integration of research and clinical expertise and experience, three iterative voting rounds (two anonymous surveys and one online consensus meeting) were performed. Statements required ≥75% agreement for inclusion.

Findings: From 9,093 publications, 69 were used to draft and support the consensus statements. A total of 30 statements relevant to six domains achieved consensus on gene therapy for hereditary hearing loss, including ethical review (1 statement), patient selection criteria (12 statements), diagnosis and preoperative evaluation (9 statements), gene therapy drug delivery (4 statements), follow-up (3 statements), and post-treatment auditory and speech rehabilitation (1 statement).

Conclusions: This consensus provides the first globally endorsed framework for gene therapy in hereditary hearing loss. It standardizes clinical trial design and patient management, accelerating translation from research to practice while ensuring safety. The guidelines are immediately applicable to OTOF-related hearing loss and adaptable to other genetic forms.

Funding: This work was supported by the National Natural Science Foundation of China, the German Research Foundation (DFG) via the Cluster of Excellence, and others.

Keywords: Translation to population health; adeno-associated virus; clinical trial; expert consensus; gene therapy; hereditary hearing loss; modified Delphi method.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests L.D.L. has received research funding from Decibel Therapeutics/Regeneron Pharmaceuticals and Amgen and has worked as an independent consultant for Akouos/Eli Lilly and the Gerson Lehrman Group. T.M. is a cofounder of OptoGenTech. R.N. has received research funding from Regeneron Pharmaceuticals/Sensorion. J.H.G. was a member of the board of Ohio Valley Voices and the scientific advisory board of Otonomy. M.B. has received research funding from Regeneron Pharmaceuticals. R.C. is the unpaid chief scientist of Otovia Therapeutics, Inc. Z.-Y.C. is a cofounder of Salubritas Therapeutics.

LinkOut - more resources